Oncology & Cancer

Immunotherapy drug shows potential to cure advanced lung cancer

In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small cell lung cancer (NSCLC), ...

Oncology & Cancer

Trial of metformin for non-small cell lung cancer

Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants ...

Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

page 1 from 15